• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "Clinical, Radiological and Pharmacokinetic Data of CT‑P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease".

作者信息

Chaman Lal Karan, Zia Zainab, Naveed Mashal, Khan Muzna, Lakho Hifza

机构信息

Department of Medicine, Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan.

Department of Medicine, Islamic International Medical College, Rawalpindi, Pakistan.

出版信息

Dig Dis Sci. 2025 Aug 5. doi: 10.1007/s10620-025-09311-5.

DOI:10.1007/s10620-025-09311-5
PMID:40764458
Abstract
摘要

相似文献

1
Comment on "Clinical, Radiological and Pharmacokinetic Data of CT‑P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease".关于“CT-P13皮下注射治疗肛瘘性肛管直肠克罗恩病患者的临床、放射学及药代动力学数据”的评论
Dig Dis Sci. 2025 Aug 5. doi: 10.1007/s10620-025-09311-5.
2
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease.CT-P13皮下注射在伴有肛瘘性肛管直肠克罗恩病患者中的临床、放射学及药代动力学数据
Dig Dis Sci. 2025 Jul 25. doi: 10.1007/s10620-025-09210-9.
3
Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.比较生物疗法在诱导瘘管性克罗恩病缓解和应答中的疗效：系统评价和随机对照试验的网络荟萃分析。
Inflamm Bowel Dis. 2023 Mar 1;29(3):367-375. doi: 10.1093/ibd/izac103.
4
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).皮下注射英夫利昔单抗（CT-P13 SC）作为克罗恩病和溃疡性结肠炎的维持治疗：两项随机对照试验（LIBERTY）开放标签扩展研究的2年结果
J Crohns Colitis. 2025 Jun 4;19(6). doi: 10.1093/ecco-jcc/jjaf060.
5
Methotrexate for induction of remission in refractory Crohn's disease.甲氨蝶呤用于诱导难治性克罗恩病缓解
Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3.
6
Methotrexate for induction of remission in refractory Crohn's disease.甲氨蝶呤用于诱导难治性克罗恩病缓解
Cochrane Database Syst Rev. 2014 Aug 6;2014(8):CD003459. doi: 10.1002/14651858.CD003459.pub4.
7
Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study.英夫利昔单抗联合手术和甲氨蝶呤治疗重度瘘管性肛门直肠克罗恩病：前瞻性研究结果。
Inflamm Bowel Dis. 2011 Jan;17(1):69-76. doi: 10.1002/ibd.21405.
8
Infliximab for maintenance of medically-induced remission in Crohn's disease.英夫利昔单抗维持克罗恩病的药物缓解
Cochrane Database Syst Rev. 2024 Feb 19;2(2):CD012609. doi: 10.1002/14651858.CD012609.pub2.
9
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.古塞库单抗静脉诱导和皮下维持治疗克罗恩病患者的疗效和安全性（GALAXI-2和GALAXI-3）：两项3期、随机、安慰剂和活性对照药对照、双盲、三模拟试验的48周结果
Lancet. 2025 Jul 26;406(10501):358-375. doi: 10.1016/S0140-6736(25)00681-6. Epub 2025 Jul 17.
10
Perianal fistulizing Crohn's disease is associated with a higher prevalence of HPV in the anorectal fistula tract. A comparative study.肛旁瘘管型克罗恩病与肛门直肠瘘管中 HPV 的更高患病率相关。一项对照研究。
Clinics (Sao Paulo). 2023 May 29;78:100219. doi: 10.1016/j.clinsp.2023.100219. eCollection 2023.

本文引用的文献

1
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease.CT-P13皮下注射在伴有肛瘘性肛管直肠克罗恩病患者中的临床、放射学及药代动力学数据
Dig Dis Sci. 2025 Jul 25. doi: 10.1007/s10620-025-09210-9.
2
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).皮下注射英夫利昔单抗（CT-P13 SC）作为炎症性肠病的维持治疗：两项随机 3 期试验（LIBERTY）。
Gastroenterology. 2024 Oct;167(5):919-933. doi: 10.1053/j.gastro.2024.05.006. Epub 2024 May 23.
3
Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
皮下注射英夫利昔单抗后血清浓度较高与炎症性肠病患者的深度缓解相关。
J Crohns Colitis. 2024 May 31;18(5):679-685. doi: 10.1093/ecco-jcc/jjad188.
4
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.随机对照试验：英夫利昔单抗 CT-P13 在炎症性肠病中的皮下与静脉输注维持治疗。
Gastroenterology. 2021 Jun;160(7):2340-2353. doi: 10.1053/j.gastro.2021.02.068. Epub 2021 Mar 5.
5
Infliximab maintenance therapy for fistulizing Crohn's disease.英夫利昔单抗用于瘘管性克罗恩病的维持治疗。
N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815.